Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Operating Expenses (2016 - 2026)

Insight Molecular Diagnostics' Other Operating Expenses history spans 6 years, with the latest figure at $15.8 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 46.35% to $15.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.9 million, a 35.58% decrease, with the full-year FY2025 number at $26.9 million, down 35.58% from a year prior.
  • Other Operating Expenses hit $15.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $4.8 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for IMDX hit a ceiling of $29.4 million in Q4 2024 and a floor of -$11.4 million in Q1 2023.
  • Historically, Other Operating Expenses has averaged $4.1 million across 5 years, with a median of $3.7 million in 2021.
  • Biggest five-year swings in Other Operating Expenses: plummeted 330.56% in 2022 and later surged 2495.51% in 2025.
  • Tracing IMDX's Other Operating Expenses over 5 years: stood at $9.1 million in 2021, then crashed by 43.09% to $5.2 million in 2022, then surged by 128.14% to $11.8 million in 2023, then soared by 149.99% to $29.4 million in 2024, then tumbled by 46.35% to $15.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for IMDX at $15.8 million in Q4 2025, $4.8 million in Q3 2025, and $4.3 million in Q2 2025.